

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION OF THE GROUP'S PRODUCT

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that the Piperacillin Sodium and Tazobactam Sodium for Injection (Specification: 4.5g) submitted by Zhuhai United Laboratories Co., Ltd., Zhongshan Branch, a wholly-owned subsidiary of the Company, with the approval of China National Medical Products Administration, passed the consistency evaluation of quality and efficacy for generic drugs (the "Consistency Evaluation").

Piperacillin Sodium and Tazobactam Sodium for Injection is a compound anti-infection drug composed by piperacillin (penicillin antibiotic) and tazobactam (β -lactamase inhibitor), applicable to treatment of moderate and severe infections caused by pneumonia, urinary tract infection, skin and soft tissue infection, septicemia, etc. Currently, this product is listed in Category B in the National Medical Insurance Drug List (2021 version). Piperacillin Sodium and Tazobactam Sodium for Injection has made the biggest single-product contribution to the sales of the Company's antibiotic finished products in 2021, and the Company is expected to continue to increase the sales and market shares of this product in the future.

The approval will further help the Company to consolidate the advantageous position in the anti-infection field. The Company will continue to devote itself to the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater values for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 10 June 2022

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.